PURPOSE: The objective of this study was to compare the differential expression of established histopathologic and biologic markers of proliferation, apoptosis, and angiogenesis in invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in a group of axillary node-negative breast cancers. PATIENTS AND METHODS: Two hundred twenty patients with axillary node-negative ILC and IDC who underwent surgery at the University of Texas M. D. Anderson Cancer Center between 1978 and 1995 had tissue available for analysis. Of these, 206 (94%) had IDC and 14 (6%) had ILC. Estrogen receptors, progesterone receptors, tumor and stromal expression of vascular endothelial growth factor receptor 2, CD44, laminin-5, E-cadherin, and topoisomerase-2 were evaluated by immunohistochemical analysis. HER2/neu and alpha6beta4 integrin were evaluated by in situ hybridization. The Fisher exact test was used to calculate significant differences between ILC and IDC. Median age was 59 years. RESULTS: Invasive lobular carcinoma was more likely to occur in patients aged > 50 years. Invasive lobular carcinoma tended to be > 2 cm (50% vs. 39%), have a nuclear grade of 1/2 (100% vs. 72%), be estrogen receptor positive (93% vs. 70%), HER2/neu negative (92% vs. 68%), have high CD44 expression (31% vs. 16%), low stromal vascular endothelial growth factor receptor 2 expression (36% vs. 47%), no E-cadherin expression (0 vs. 90%), and low laminin-5 expression (15% vs. 25%), compared with IDC. CONCLUSION: Invasive lobular carcinoma and IDC might be distinct histologic types of breast cancer with different expression of biologic markers. These differences, not all being statistically significant in this small study, might generate hypotheses to develop tailored options for future systemic therapy.
PURPOSE: The objective of this study was to compare the differential expression of established histopathologic and biologic markers of proliferation, apoptosis, and angiogenesis in invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in a group of axillary node-negative breast cancers. PATIENTS AND METHODS: Two hundred twenty patients with axillary node-negative ILC and IDC who underwent surgery at the University of Texas M. D. Anderson Cancer Center between 1978 and 1995 had tissue available for analysis. Of these, 206 (94%) had IDC and 14 (6%) had ILC. Estrogen receptors, progesterone receptors, tumor and stromal expression of vascular endothelial growth factor receptor 2, CD44, laminin-5, E-cadherin, and topoisomerase-2 were evaluated by immunohistochemical analysis. HER2/neu and alpha6beta4 integrin were evaluated by in situ hybridization. The Fisher exact test was used to calculate significant differences between ILC and IDC. Median age was 59 years. RESULTS:Invasive lobular carcinoma was more likely to occur in patients aged > 50 years. Invasive lobular carcinoma tended to be > 2 cm (50% vs. 39%), have a nuclear grade of 1/2 (100% vs. 72%), be estrogen receptor positive (93% vs. 70%), HER2/neu negative (92% vs. 68%), have high CD44 expression (31% vs. 16%), low stromal vascular endothelial growth factor receptor 2 expression (36% vs. 47%), no E-cadherin expression (0 vs. 90%), and low laminin-5 expression (15% vs. 25%), compared with IDC. CONCLUSION:Invasive lobular carcinoma and IDC might be distinct histologic types of breast cancer with different expression of biologic markers. These differences, not all being statistically significant in this small study, might generate hypotheses to develop tailored options for future systemic therapy.
Authors: Esther H Lips; Rita A Mukhtar; Christina Yau; Jorma J de Ronde; Chad Livasy; Lisa A Carey; Claudette E Loo; Marie-Jeanne T F D Vrancken-Peeters; Gabe S Sonke; Donald A Berry; Laura J Van't Veer; Laura J Esserman; Jelle Wesseling; Sjoerd Rodenhuis; E Shelley Hwang Journal: Breast Cancer Res Treat Date: 2012-09-08 Impact factor: 4.872
Authors: Aphrodite Nonni; Flora Zagouri; Theodoros N Sergentanis; Andreas C Lazaris; Efstratios S Patsouris; George C Zografos Journal: Virchows Arch Date: 2007-10-09 Impact factor: 4.064
Authors: Alvaro Ruibal; Pablo Aguiar; Maria Del Camen Del Río; Primitiva Menéndez; José Ignacio Arias; Michel Herranz Journal: Mol Clin Oncol Date: 2015-08-28
Authors: Jeroen F Vermeulen; Robert A H van de Ven; Cigdem Ercan; Petra van der Groep; Elsken van der Wall; Peter Bult; Matthias Christgen; Ulrich Lehmann; Juliet Daniel; Paul J van Diest; Patrick W B Derksen Journal: PLoS One Date: 2012-05-25 Impact factor: 3.240
Authors: Seung Taek Lim; Jong Han Yu; Heung Kyu Park; Byung In Moon; Byung Kyun Ko; Young Jin Suh Journal: World J Surg Oncol Date: 2014-03-13 Impact factor: 2.754
Authors: Hanna M Romanska; Piotr Potemski; Magdalena Krakowska; Magdalena Mieszkowska; Shalini Chaudhri; Radzisław Kordek; Robert Kubiak; Valerie Speirs; Andrew M Hanby; Rafał Sadej; Fedor Berditchevski Journal: Br J Cancer Date: 2015-09-29 Impact factor: 7.640